pyrroles has been researched along with Leiomyosarcoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inatsu, H; Kitamura, K; Nakashima, K | 1 |
| Boichuk, S; Dunaev, P; Galembikova, A; Khaibullina, S; Khusnutdinov, R; Lombardi, V; Ramazanov, B; Zykova, S | 1 |
| Bosscher, JR; Brown, J; Debernardo, RL; Gehrig, PA; Hartenbach, EM; Hensley, ML; McCourt, CK; Scribner, DR; Sill, MW | 1 |
| Agresta, S; Antonia, S; Calitri, CE; Chiappori, A; D'Amato, G; Dean, M; Garrett, C; Han, G; Mahmood, ST; Schell, MJ; Vigil, CE; Zhao, X | 1 |
2 trial(s) available for pyrroles and Leiomyosarcoma
| Article | Year |
|---|---|
Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Indoles; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib; Uterine Neoplasms | 2009 |
Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.
Topics: Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histiocytoma, Malignant Fibrous; Humans; Indoles; Leiomyosarcoma; Liposarcoma; Male; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Recurrence; Retreatment; Sarcoma; Sunitinib; Survival Rate | 2011 |
2 other study(ies) available for pyrroles and Leiomyosarcoma
| Article | Year |
|---|---|
Primary Cardiac Leiomyosarcoma: A 27-Month Survival with Surgery and Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Docetaxel; Doxorubicin; Fatal Outcome; Gemcitabine; Heart Neoplasms; Humans; Ifosfamide; Indoles; Leiomyosarcoma; Life Support Care; Male; Mesna; Pyrroles; Sunitinib; Taxoids | 2017 |
Ethyl-2-amino-pyrrole-3-carboxylates are novel potent anticancer agents that affect tubulin polymerization, induce G2/M cell-cycle arrest, and effectively inhibit soft tissue cancer cell growth in vitro.
Topics: Antineoplastic Agents; Bone Neoplasms; Carboxylic Acids; Cell Death; Cell Growth Processes; Cell Line, Tumor; G2 Phase Cell Cycle Checkpoints; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Leiomyosarcoma; M Phase Cell Cycle Checkpoints; Osteosarcoma; Pyrroles; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Tubulin; Tubulin Modulators | 2016 |